Items Tagged ‘renal cell carcinoma’

May 10th, 2016

Cabometyx® Approved for Kidney Cancer

By

The United States Food and Drug Administration (FDA) has approved the kinase inhibitor Cabometyx (cabozantinib) for the treatment of renal cell carcinoma (kidney cancer). The approval is for patients with advanced renal cell carcinoma who have already been treated with prior anti-angiogenic therapy. Each year in the United States, more than 61,000 people are diagnosed […]

View full entry

Tags: Cabometyx, cabozantinib, General Renal Cancer, kidney cancer, kinase inhibitor, metastatic, News, rcc, Renal Cancer, renal cell carcinoma


March 15th, 2016

Clinical Study Evaluating Dalantercept in Combination with Axitinib Now Enrolling Advanced RCC Patients Nationwide

By

If you are battling kidney cancer, otherwise known as renal cell carcinoma (RCC), The DART Study may be the next treatment option for you to consider. Dalantercept, in combination with axitinib, an FDA approved therapy, aims to halt the growth and spread of RCC. The DART Study is testing the safety and efficacy of dalantercept in combination with axitinib and is […]

View full entry

Tags: axitinib, clinical trial, dalantercept, DART study, General Renal Cancer, kidney cancer, News, rcc, Renal Cancer, renal cell carcinoma, study


October 12th, 2015

Opdivo® Improves Survival in Kidney Cancer

By

The immunotherapy agent, Opdivo® (nivolumab), improves survival in kidney cancer compared to the standard treatment, Afinitor® (everolimus). These results were recently published in the New England Journal of Medicine. About Renal Cell Carcinoma Each year in the United States, more than 61,000 people are diagnosed with kidney cancer. The most common type of kidney cancer […]

View full entry

Tags: afinitor, kidney cancer, metastatic, News, opdivo, rcc, Renal Cancer, renal cell carcinoma


July 29th, 2015

Study of Opdivo® versus Afinitor® Stopped Early when Opdivo Demonstrated Better Survival

By

Patients with advanced or metastatic kidney cancer who are treated with Opdivo® (nivolumab) have better overall survival than those treated with Afinitor® (everolimus), according to findings from a Phase III clinical trial. Because the improved survival with Opdivo was apparent sooner than expected, the trial has been stopped early. Each year in the United States, […]

View full entry

Tags: General Renal Cancer, kidney cancer, News, nivolumab, opdivo, rcc, Renal Cancer, renal cell carcinoma


May 18th, 2015

axitinib

By

Class: Biological Therapy Generic Name: axitinib Trade Name: Inlyta® For which conditions is this drug approved? Inlyta is approved for the treatment of advanced renal cell carcinoma (kidney cancer) when prior treatment hasn’t worked. What is the mechanism of action? Inlyta is a kinase inhibitor. These drugs work by blocking the action of enzymes called kinases, […]

View full entry

Tags: A, Biological Therapy, Drug Dictionary, Inlyta, kidney cancer, renal cell carcinoma